



Five Star Safety Ratings awarded to Piramal Enterprises Ltd. by British Safety Council

Piramal is the only Indian Pharmaceutical Company to have received this recognition this year

Mumbai, October 07, 2013: Piramal Enterprises achieved the British Safety Council (BSC) Five-Star Safety Award for the Digwal pharma solutions' site, near Hyderabad. Piramalis the only Indian pharmaceutical company this year to achieve such a prestigious rating. This award recognises the company's adherence to world class safety and compliance with the best industry practices worldwide.

Commenting on the appreciation **Mr. Vijay Shah, Executive Director & COO, Piramal Enterprises** said: "At Piramal, Environment, Health & Safety (EHS) is embedded in our very philosophy of business. The Digwal site underwent a stringent 4 day audit from 12th to 16th August, 2013 led by a delegate from British Safety Council (BSC), UK. I am happy to note that the audit results declared on 10th September, 2013 scored Digwal site at a commendable 94.58%. The Five Star Award of BSC, is highly reputed and is awarded in recognition of world class safety practices. We are the only Indian Pharma company this year to have received this prestigious award. This indeed is noteworthy."

The British Safety Council audit is an internationally recognised system, used by leading organisations worldwide to benchmark their health, safety and environment (HSE) management systems against the best practices. The 5-star audit concentrates on five sections, viz: safety organisation, management control system, fire control systems, measurement and control systems and workplace implementation. Piramal's high score credits the site with a 5-star rating (Grading of 92 - 100 per cent) which is a world-class benchmark standard.

Among many other areas of strength in Piramal's safety management systems, the BSC auditor commended the management's commitment and efforts to achieve excellence in occupational health and safety.

About Piramal Enterprises Ltd:

Piramal Enterprises is one of India's largest diversified companies, with a presence in pharmaceutical, financial services and information management sectors. Piramal Enterprises had consolidated revenues of over \$ 650 million in FY2013. In the pharmaceutical space, PEL is one of leading custom manufacturing player globally, has presence in the global critical care segment with a portfolio of inhalation and injectible anesthetics and its OTC business is ranked no. 7 in India. PEL is also engaged in drug discovery & research and has strong pipeline of development products. In the financial services space, PEL has a real estate focused PE fund – Indiareit and a NBFC that is focused on lending to real estate and education sector. PEL's information management business, Decision Resources Group is a leading provider of information based services to the healthcare industry.

For media enquiries, please contact:

PIRAMAL ENTERPRISES	PUBLIC RELATIONS CONSULTANTS
AkanshaPradhan / Riddhi Goradia	Janhavi Bellare/ Mugdha Joshi
Corporate Communications,	MSL India
Piramal Group	Tel: +91-22-33557500
Contact: +91 22 3351 4082 / 4083	Mobile: +91 9322854508/ + 91 9820326645

akansha.pradhan@piramal.com

riddhi.goradia@piramal.com

Janhavi.bellare@msslgroup.com /

mugdha.joshi@msslgroup.com